The curtain closed last week on the 2017 American Society of Clinical Oncology (ASCO) meeting. Like the past couple of meetings, immunotherapies received the lion's share of attention and created the most buzz, which is hardly surprising since the ability to turn cold tumors hot, either with new monotherapies or an ever-expanding number of combination therapies, is certainly a promising direction for the future of cancer research.